Share
We offer testing like:
- BCR signalling inhibitor
- anti CD20 antibodies
- chemo-therapy
and their combinations on a panel of B cell lymphoma cell lines and primary CLL samples.
This technology can be used for:
drug testing in pharma industry
Equipment
- cell lines
- primary samples from patient
- PDX mouse models
Literature
Pavlasova, G; Borsky, M; Seda, V; Cerna, K; Osickova, J; Doubek, M; Mayer, J; Calogero, R; Trbusek, M; Pospisilova, S; Davids, MS; Kipps, TJ; Brown, JR; Mraz, M, 2016: Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. BLOOD 128(12), p. 1609 - 1613, doi: 10.1182/blood-2016-04-709519
Mraz, M; Zent, CS; Church, AK; Jelinek, DF; Wu, XS; Pospisilova, S; Ansell, SM; Novak, AJ; Kay, NE; Witzig, TE; Nowakowski, GS, 2011: Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. BRITISH JOURNAL OF HAEMATOLOGY 155(1), p. 53 - 64, doi: 10.1111/j.1365-2141.2011.08794.x
Pavlasova, G; Borsky, M; Svobodova, V; Oppelt, J; Cerna, K; Novotna, J; Seda, V; Fojtova, M; Fajkus, J; Brychtova, Y; Doubek, M; Pospisilova, S; Mayer, J; Mraz, M, 2018: Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. LEUKEMIA 32(9), p. 2028 - 2031, doi: 10.1038/s41375-018-0211-0
Cerna, K; Oppelt, J; Chochola, V; Musilova, K; Seda, V; Pavlasova, G; Radova, L; Arigoni, M; Calogero, RA; Benes, V; Trbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S; Mraz, M, 2019: MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. LEUKEMIA 33(2), p. 403 - 414, doi: 10.1038/s41375-018-0230-x
